As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the CyberMega Smart Treadmill across ...
Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease. Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Bre ...
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ; ...
CytomX expects to use the net proceeds from this offering for the continued development of Varseta-M and other pipeline programs. CytomX expects to use any remaining net proceeds from this offering ...
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...
A 2026 consumer warning report examining DentaBiome's oral postbiotic formula, how FabM acid-lock and 30-second kitchen method claims relate to published research, the ingredient research context ...
A 2026 company-issued informational report covering NatureGlyco's product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The ...
SugarHarmony Research has released ingredient reference materials outlining the compounds associated with Blood Sugar Harmony Liquid Drops, citing scientific references and ingredient context as part ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results